Market Access Impact: Haemophilia B (EU5) 2018

Maximum Purchase:
1 unit
Publication Date:
June 2018
Adding to cart… The item has been added

Market barriers affect 21 percent of haemophilia B prescriptions in Europe. Is your brand losing out?

Market barriers are affecting over 21 percent of all haemophilia B prescriptions in Europe, and certain brands are losing out on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: Haemophilia B (EU5) [2018].

Based on a survey of 150 haematologists from the EU5 countries (France, Germany, Italy, Spain and the UK), the report covers 7 major therapies from Shire, SOBI, CSL Behring, Novo Nordisk and Pfizer. Handy graphs and charts reveal which  of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • Barriers affect over 21 percent of all prescriptions. And some brands are losing out on market share opportunities because of them. Is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Three brands see the biggest share increases. But are they so far ahead that other brands can’t catch up? And is your brand leading, or in the chasing pack?
  • One brand sees a significant loss. Close to 40 percent of physicians prescribe this brand, so which barriers are slowing down adoption? And can this be prevented?
  • Eliminating barriers would close gaps across the table. And certain products would move up several places, suggesting an improved market access strategy could drive significant market share gains.
  • Perception could be a problem for some brands. Across all 7 brands, awareness and a willingness to use is high. But for two brands, over 10 percent of physicians wouldn’t even consider using them? Is it your brand?

Insight into 7 Major Haemophilia B Treatments

  • Alprolix (eftrenonacog alfa; Swedish Orphan Biovitrum)
  • BeneFIX (nonacog alfa; Pfizer)
  • Feiba (Anti-Inhibitor Coagulant Complex; Shire)
  • Idelvion (albutrepenonacog alfa; CSL Behring)
  • MonoNine (Coagulation Factor IX (human); CSL Behring)
  • Rixubis (nonacog gamma; Shire)
  • Refixia (nonacog beta pegol; Novo Nordisk)

Exploring Important Market Access Issues

Market Access Impact: Haemophilia B (EU5) explores key issues affecting haemophilia B drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 haematologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with haemophilia B in total in the last month

We conducted the survey between June 4-15, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at